- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07892144
Effects of Low-Load Blood Flow Restriction Resistance Training With and Without Hip Abductor Strengthening in Patients With Knee Osteoarthritis (BFR) (yes)
Effects of Low-Load Blood Flow Restriction Resistance With and Without Hip Abductor Strength Training on Pain, Range of Motion, Strength and Function in Patients With Knee Osteoarthritis
This study aims to compare the effects of low-load Blood Flow Restriction (BFR) resistance training with and without hip abductor strengthening in patients with knee osteoarthritis. It will evaluate the effectiveness of both treatment approaches in reducing knee pain, improving range of motion, increasing muscle strength, and enhancing functional ability. The study will determine which intervention provides better clinical outcomes in patients with knee osteoarthritis.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistán, 54000
- University of Management & Technology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Both genders.
- Age 40-60 years.
- BMI (kg/m 2 ) < 30
- Have unilateral or bilateral knee OA.
- Have radiographic OA severity of Kellgren-Lawrence Grade I-II.
- Knee pain ≥3 months.
- Report pain intensity of ≥4-6/1 0 on NPRS
- Be able to walk independently without assistive devices
Exclusion Criteria:
- Total Knee replacement
- Deep venous thrombosis.
- Severe Cardiovascular disorders.(such as Acute myocardial
- infarction, peripheral arterial disease)
- Uncontrolled hypertension and diabetes.
- Acute knee injury within the last 6 months.
- Significant ligament tears (ACL, PCL, MCL, LCL).
- Knee surgery within the last 6-1 2 months.
- Lower limb Fractures
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Low-Load Blood Flow Restriction Resistance Training
|
Participants will receive supervised low-load BFR training targeting quadriceps and hamstrings through seated knee extensions, leg presses (bilateral/unilateral), and progressive mini squats at 20-30% of 1RM.Each exercise includes 4 sets (30-15-15-15 repetitions), with 30-60 seconds of rest between sets while the cuff remains inflated, followed by immediate deflation after the final set. |
|
Experimental: Hip abductor strength training followed by low-load BFR resistance training
|
Participants will receive hip abductor strengthening for Weeks 2-4, followed by BFR resistance training during Weeks 5-6, under physiotherapist supervision. Exercises include side-lying hip abduction, clamshells, standing resisted hip abduction, and lateral band walks (3 sets of 10-15 repetitions or 10 lateral steps per direction), with 60-second rest intervals. Training will begin with bodyweight exercises, progressing to TheraBand resistance from Week 2, without BFR cuff application during hip exercises. Weeks 5-6: Participants will receive BFR training (knee extensions and leg presses) at 20-30% of 1RM, 70% arterial occlusion pressure (AOP), and 4 sets of 30-15-15-15 repetitions. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Numeric Pain Rating Scale
Periodo de tiempo: Baseline and 6 weeks post treatment
|
11-point numeric with 0 representing No pain, 1-3 representing Mild Pain (nagging, annoying, interfering little with ADLs), 4-6 representing Moderate Pains (interferes significantly with ADLs), 7-10 representing Sever Pain |
Baseline and 6 weeks post treatment
|
|
Western Ontario And McMasters Universities Osteoarthritis Index
Periodo de tiempo: Baseline and 6 weeks post treatment
|
The WOMAC is a disease-specific questionnaire designed to assess symptoms and functional limitations in individuals with knee and hip osteoarthritis. It consists of 24 items divided into three domains: Pain (5 items), Stiffness (2 items), and Physical.Function (1 7 items). The WOMAC is widely used to evaluate the impact of osteoarthritis on daily activities and quality of life.Higher WOMAC scores indicate greater pain, stiffness, and functional disability, whereas lower scores represent betterfunctional status and symptom improvement. |
Baseline and 6 weeks post treatment
|
|
Goniometer
Periodo de tiempo: Baseline and 6 weeks post treatment
|
A goniometer is a reliable clinical tool used to measure knee flexion and extension ROM in patients with knee osteoarthritis, assess joint mobility, monitor disease progression, and evaluate rehabilitation outcomes. Normal knee flexion is approximately 135°-140° and extension is 0°. Reduced ROM indicates stiffness, pain, or functional limitations. |
Baseline and 6 weeks post treatment
|
|
Handheld Dynamometer
Periodo de tiempo: Baseline and 6 weeks post treatment
|
A handheld dynamometer (HHD) is a portable, objective tool used to measure isometric muscle strength at a fixed joint position. It records maximum muscle force in Newtons (N) or kilograms-force (kgf), with higher values indicating greater muscle strength. |
Baseline and 6 weeks post treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Short form 1 2 Health Survey
Periodo de tiempo: Baseline and 6 weeks post treatment
|
The SF-12 is a validated, reliable, and shorter version of the SF-36 that assesses physical (PCS) and mental (MCS) components of quality of life in knee osteoarthritis patients. Lower baseline scores indicate physical impairment or emotional burden, while increased post-intervention scores reflect improved physical and mental health. A change of approximately 3-5 points may be considered clinically meaningful, depending on the population and scoring method. |
Baseline and 6 weeks post treatment
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades musculoesqueléticas
- Artritis
- Enfermedades Articulares
- Enfermedades reumáticas
- Osteoartritis
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor
- Artrosis, Rodilla
- Actividad motora
- Movimiento
- Fenómenos fisiológicos musculoesqueléticos
- Fenómenos fisiológicos musculoesqueléticos y neuronales
- Terapéutica
- Modalidades de fisioterapia
- Atención al paciente
- Terapia de ejercicio
- Rehabilitación
- Cuidado por los convalecientes
- Continuidad de la atención al paciente
- Acondicionamiento físico, humano
- Ejercicio
- Entrenamiento de resistencia
Otros números de identificación del estudio
- RE-169-2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Marco de tiempo para compartir IPD
6 months after the publication of the manuscript
Criterios de acceso compartido de IPD
The data can be requested from the corresponding author.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .